On April 29, 2026, the 16th Accelerator Pitch Day, hosted by Moordn Institute in collaboration with leading partner institutions, was successfully held in Guangzhou. The event brought together more than 50 representatives from investment and financial institutions, alongside over 100 entrepreneurs and industry leaders from the Greater Bay Area, showcasing some of the region’s most promising innovation-driven ventures.
Against this competitive backdrop, NeuDirection emerged as the top-ranked company of the event. Following a rigorous evaluation process and live scoring by an expert panel, the company achieved the highest overall score among all presenting teams and was awarded the event’s top honor—the “Excellence Award”—positioning it as one of the most closely watched companies of the session.
Advancing a First-in-Class Approach to Amblyopia Treatment
During the pitch session, NeuDirection highlighted its lead pipeline asset: a first-in-class investigational therapy targeting the visual cortex for the treatment of amblyopia. Built on cutting-edge neuroscience insights, the program departs from conventional peripheral intervention strategies by directly modulating central visual pathways, offering a differentiated mechanism of action with strong clinical potential.
The candidate has received Investigational New Drug (IND) approvals in both China and the United States and has entered the clinical development stage—marking a key milestone in its global development strategy. The company’s founding team is led by internationally recognized experts in neuroscience, with deep expertise in visual cortical plasticity and GPCR-targeted therapeutics.
Strong Validation from Investors and Industry Experts
The judging panel—comprising prominent investors and industry specialists—conducted a comprehensive assessment of each project across multiple dimensions, including technological innovation, market opportunity, business model, team capability, and execution feasibility.
Following live Q&A sessions and scoring, NeuDirection secured the highest aggregate score among all participants. Judges and investors noted the company’s compelling positioning in the amblyopia treatment space, highlighting the combination of significant unmet clinical need and high technical barriers to entry. Several panelists commented on the company’s strong potential for long-term growth and category leadership.
Recognition Underscores Leadership in Innovation
Securing first place and the Excellence Award marks a significant milestone for NeuDirection. The recognition not only underscores the company’s scientific and strategic strengths in innovative drug development but also enhances its visibility within the global investment and biopharmaceutical ecosystem. It reflects strong external validation of the company’s technological maturity, commercial potential, and execution capabilities.
Accelerating Global Development
Looking ahead, NeuDirection will continue to advance its pipeline in central nervous system disorders, with a focus on accelerating clinical development and expanding its international footprint. The company remains committed to engaging with global capital markets and strategic partners to drive the efficient translation of breakthrough science into transformative therapies for patients worldwide.
About NeuDirection
NeuDirection is a biopharmaceutical company dedicated to the discovery and development of innovative therapies for central nervous system disorders. With a strategic focus on visual system diseases, the company aims to address significant unmet medical needs through first-in-class mechanisms, advancing China-originated innovation onto the global stage.